Related Experiment Videos
Thromboxane and prostacyclin changes during cardiopulmonary bypass with and without pulsatile flow
The Journal of Thoracic and Cardiovascular Surgery
|August 1, 1982
Summary
Pulsatile cardiopulmonary bypass reduces harmful thromboxane (TxB2) and increases beneficial prostacyclin, potentially lowering heart attack risk during surgery. This study compared pulsatile vs. nonpulsatile flow effects on these key substances.
Area of Science:
- Cardiovascular Surgery
- Biomedical Engineering
- Pharmacology
Background:
- Nonpulsatile cardiopulmonary bypass increases thromboxane (TxB2), a platelet aggregator and vasoconstrictor.
- Pulsatile flow may reduce perioperative myocardial infarction and hormonal stress during bypass.
Purpose of the Study:
- To assess the impact of pulsatile blood flow on plasma thromboxane B2 (TxB2) and 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) during cardiopulmonary bypass.
- To compare these effects between pulsatile and nonpulsatile bypass methods.
Main Methods:
- Serial measurement of thromboxane B2 (TxB2) and 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) in two groups of eight patients undergoing cardiopulmonary bypass.
- One group received routine nonpulsatile bypass; the other received pulsatile flow bypass.
Main Results:
- Nonpulsatile bypass significantly increased TxB2 and prostacyclin levels.
- Pulsatile bypass also increased TxB2, but to a significantly lower peak concentration compared to nonpulsatile bypass.
- Pulsatile bypass resulted in significantly higher prostacyclin levels than nonpulsatile bypass.
- No significant differences in plasma hemoglobin, hematocrit, or platelet count were observed between groups.
Conclusions:
- Pulsatile flow during cardiopulmonary bypass favorably alters thromboxane and prostacyclin profiles.
- It promotes the production of prostacyclin, a coronary vasodilator and platelet disaggregant.
- This modulation may contribute to the clinical benefits observed with pulsatile flow bypass.